According to studies conducted by the Future Sustainable Food Systems research group at the University of Helsinki in collaboration with the VTT Technical Research Centre…
Posts published by “Dennis Carey”
As a significant contributor and a thorough public health professional, Dennis's professional profile is highly impressive and his association as a contributing writer at Health Rapid is highly valued. He has considerable experience in writing for various medical and scientific documents such as literature reviews, scientific publications and is best known for his tremendous contribution as a medical writer. He also has significant experience for writing in government websites such as the National Institutes of Health which explains his sheer mettle and accuracy.
Once again, it’s that time of year! With the year 2021 behind us, we’re taking a look back at the Biotech advancements that impacted the…
For AC Immune CEO Andrea Pfeifer, Ph.D., it’s all about biomarkers. The modest Roche-partnered business is capitalising on the tremendous moment underway in research for…
On Friday, Dec. 17, state authorities and university leaders toured Stratatech Corp. in University Research Park in Madison, demonstrating Madison inventiveness. Stratatech is a great…
Pfizer is coming, therefore biotech companies around the world should clean up their store windows, clean up their benches, and straighten up their lab coats,…
The US based biotech firm said that its synthetic Antibody treatment designed to combat covid-19 may be ineffective on the Omicron variant. It further said…
Linus Biotechnology Inc., a leader in precision exposome sequencing, said today that the FDA’s Center for Devices and Radiological Health has designated the Company’s StrandDxTM-ASD…
ImStem Biotechnology, Inc., a biopharmaceutical company developing human embryonic stem cell (ESC)-derived mesenchymal stem cells, has dosed the first U.S. multiple sclerosis (MS) patient with…
Today, Tiamat Sciences, a Biotechnology startup, announced a $3 million seed funding round headed by True Ventures of Silicon Valley, with participation from Social Impact…
With a $1 billion asset deal with Arrowhead Pharmaceuticals, GlaxoSmithKline is making its first big step into treating nonalcoholic steatohepatitis (NASH), a fatty liver disease.…